Detalles de la búsqueda
1.
Final analysis of the phase 3 randomized clinical trial comparing HD201 vs. referent trastuzumab in patients with ERBB2-positive breast cancer treated in the neoadjuvant setting.
BMC Cancer
; 23(1): 112, 2023 Jan 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-36721174
2.
Long-term efficacy and safety of CT-P6 versus trastuzumab in patients with HER2-positive early breast cancer: final results from a randomized phase III trial.
Breast Cancer Res Treat
; 188(3): 631-640, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34148205
3.
CT-P6 compared with reference trastuzumab for HER2-positive breast cancer: a randomised, double-blind, active-controlled, phase 3 equivalence trial.
Lancet Oncol
; 18(7): 917-928, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28592386
4.
Histopathological characterization of ulcerated breast cancer and comparison to their non-ulcerated counterparts.
Tumour Biol
; 36(5): 3423-8, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25544709
5.
Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 8(5): 698-705, 2022 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35238873
Resultados
1 -
5
de 5
1
Próxima >
>>